Results 241 to 250 of about 156,514 (326)

Population Pharmacokinetic and Exposure‐Efficacy Analysis of Baloxavir Marboxil for Influenza Treatment and Post‐Exposure Prophylaxis in Children

Clinical Pharmacology &Therapeutics, EarlyView.
Baloxavir acid (baloxavir), the active metabolite of the prodrug baloxavir marboxil, is a selective inhibitor of the influenza virus cap‐dependent endonuclease. The population pharmacokinetic (popPK) profile of baloxavir in adults/adolescents has been described previously.
Sylvie Retout, Stefan De Buck, Jacques Gaudreault, Sébastien Jolivet, Vincent Duval, Valérie Cosson, Marie‐Laure Delporte   +6 more
wiley   +1 more source

Randomized Placebo Controlled Open Labelled Comparison of Efficacy of Diclofenac Transdermal Patch in Post Operative Pain

, 2019
Niranjan Salunke, Maniram Kranthi Kumar, Yogesh Yogesh, Meher Tabassum, P. L. Pravallika, M. Sampoorna, P. Pranathi Rao   +6 more
openalex   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Dismantling open-label placebos and their rationales: A remote 4-arm randomized controlled trial protocol

Léo Druart, Parker S. Lay, Grayson L. Baird, Francesca L. Beaudoin, Julia Totten, Jodi L. Sutherland, Rochelle K. Rosen, Michael H. Bernstein   +7 more
openalex   +1 more source

Open-Label Placebos for Antidepressant Discontinuation Symptoms: A Series of N-of-1 Trials [PDF]

Amke Müller, Stefan Konigorski, Tahmine Fadai, Claire V. Warren, Lena Koschik, Wei Liu, Ulrike Bingel, Winfried Rief, Irina Falkenberg, Tilo Kircher, Yvonne Nestoriuc   +10 more
openalex   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Evaluation of Jati (Jasminum grandiflorum L.) mouthwash and Jati Kwatha (decoction) in Mukhapaka (aphthous stomatitis): An open-label, randomized, placebo-controlled clinical study

G. Balakrishnan, Arun Mohanan, N V Ramesh   +2 more
openalex   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

The Possibility of Open-Label Use of Placebo in Healthcare Practice: A Systematic Review of Recent Clinical Trials. [PDF]

Cureus
Tao FCW, Ghafoor F, Yang N.
europepmc   +1 more source

Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CM313 in Healthy Participants: An Open‐Label/Double‐Blind, Randomized, Placebo‐Controlled Phase 1 Trial

Shuyan Yu, Junzhen Wu, Junxue Zhao, Jinjie He, Hongyue Yan, Xiang Zhang, Yifan Yang, Song Han, Qiaoyun Hou, Bujing Guo, Yudian Qiu, Bo Chen, Yu Xue, Jing Zhang   +13 more
openalex   +1 more source